share_log

藥明康德：根據2019年A股激勵計劃預留授予的限制性A股股票解除限售及上市流通

WUXI APPTEC: UNLOCKING AND TRADING OF THE RESTRICTED A SHARES GRANTED UNDER THE RESERVED GRANT OF THE 2019 A SHARE INCENTIVE PLAN

香港交易所 ·  Mar 18 08:29
Summary by Moomoo AI
药明康德宣布，根據2019年A股激勵計劃，公司已於2024年3月18日批准解除限售並上市流通101,376股限制性A股股票。該批股票屬於預留授予第三個解除限售期，涉及12名激勵對象，包括高層及中層管理人員及技術骨幹。此次解除限售是在達成公司及個人業績考核目標後進行，且無違反相關法律法規。解除限售的限制性A股股票將於2023年9月18日開始上市流通。
药明康德宣布，根據2019年A股激勵計劃，公司已於2024年3月18日批准解除限售並上市流通101,376股限制性A股股票。該批股票屬於預留授予第三個解除限售期，涉及12名激勵對象，包括高層及中層管理人員及技術骨幹。此次解除限售是在達成公司及個人業績考核目標後進行，且無違反相關法律法規。解除限售的限制性A股股票將於2023年9月18日開始上市流通。
According to the 2019 A Share Incentive Plan, the Company has approved the delisting and placing on the market of 101,376 shares of Restricted A Shares on March 18, 2024, under the 2019 A-share incentive plan. This batch of shares is part of the reserved grant for the third delisting period involving 12 inductees, including senior and middle management and the technical backbone. This deregistration is made after the Company and Personal Performance Assessment objectives have been met and does not violate any relevant laws and regulations. Restricted shares of Class A shares lifted will begin public circulation on September 18, 2023.
According to the 2019 A Share Incentive Plan, the Company has approved the delisting and placing on the market of 101,376 shares of Restricted A Shares on March 18, 2024, under the 2019 A-share incentive plan. This batch of shares is part of the reserved grant for the third delisting period involving 12 inductees, including senior and middle management and the technical backbone. This deregistration is made after the Company and Personal Performance Assessment objectives have been met and does not violate any relevant laws and regulations. Restricted shares of Class A shares lifted will begin public circulation on September 18, 2023.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more